O. Viganò

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).

G. di Perri, A. Calcagno, A. D’Avolio, 2015, The Journal of antimicrobial chemotherapy.

T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy

P. Narciso, A. Corpolongo, V. Tozzi, 2008, Biologics : targets & therapy.

Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients.

S. Mercadante, G. di Perri, A. Calcagno, 2014, Current HIV research.